DDC
PGNX

DF Dent & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

DF Dent & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,600
Closed -$116K – 245
2018
Q1 		$116K Buy
+15,600
New +$104K ﹤0.01% 234

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

DF Dent & Co's PGNX Position: Q2 2018 in Review

DF Dent & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2018, closing a stake of 15,600 shares — an estimated $116K sold.

DF Dent & Co first reported a position in PGNX in Q1 2018 and held it in 1 quarter. The position peaked at $116K in Q1 2018. 155 funds tracked by Wall St. Rank hold PGNX as of Q2 2018.

  • DF Dent & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • DF Dent & Co sold 15,600 Progenics Pharmaceuticals Inc shares in Q2 2018, an estimated $116K.
  • DF Dent & Co first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 1 quarter.
  • DF Dent & Co's Progenics Pharmaceuticals Inc position peaked at $116K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2018.

Based on DF Dent & Co's 13F filing for Q2 2018, filed 15 Aug 2018.